Neurology

DEA Reschedules Cannabidiol, Paving the Way to Market

The US Drug Enforcement Administration has moved the FDA-approved cannabis-based drug for Lennox-Gastaut syndrome and Dravet syndrome from Schedule I to V, concluding that it has a low potential for abuse.
Medscape Medical News

Source link




Related posts

What Makes Some People Creative Thinkers and Others Analytical

Newsemia

Could the Burnout You’re Feeling Actually Be Compassion Fatigue?

Newsemia

Get Relief from Pain with this Effective Therapy

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy